Wockhardt (NSE:WOCKPHARMA) Other Stockholders Equity: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WOCKPHARMA Wockhardt Ltd NSE:WOCKPHARMA
60 GF Score
Price ₹1,886.30
GF Value ₹1,464.07
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Wockhardt Other Stockholders Equity?

Wockhardt NSE:WOCKPHARMA +3.04% 60 Other Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:WOCKPHARMA with a GF Score™ of 60/100 and a GF Value™ of ₹1,464.07 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Wockhardt's Other Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

Wockhardt's quarterly Other Stockholders Equity increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹13,370 Mil) but then declined from Mar. 2026 (₹13,370 Mil) to Jun. 2026 (₹0 Mil).

Wockhardt's annual Other Stockholders Equity increased from Mar. 2024 (₹9,620 Mil) to Mar. 2025 (₹10,260 Mil) and increased from Mar. 2025 (₹10,260 Mil) to Mar. 2026 (₹13,370 Mil).

Wockhardt Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Wockhardt's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wockhardt Other Stockholders Equity Chart

Wockhardt Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,860.00 9,540.00 9,620.00 10,260.00 13,370.00

Wockhardt Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 44,860.00 0.00 13,370.00 0.00
NSE:WOCKPHARMA
60GF Score
Wockhardt Ltd NSE:WOCKPHARMA
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wockhardt Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹0 Mil mean?
Wockhardt (NSE:WOCKPHARMA) has a Other Stockholders Equity of ₹0 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Wockhardt and its competitors.
Is Wockhardt's Other Stockholders Equity too high?
Wockhardt's current Other Stockholders Equity is ₹0 Mil. Overall, Wockhardt has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Other Stockholders Equity compare to ZTS?
Wockhardt's Other Stockholders Equity of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Wockhardt and its competitors. Wockhardt's current Other Stockholders Equity is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (NSE:WOCKPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,464.07, compared to a current price of ₹1,886.30 — trading 28.8% above its estimated fair value. The current Other Stockholders Equity is ₹0 Mil. Wockhardt's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Wockhardt (NSE:WOCKPHARMA), the current Other Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wockhardt (NSE:WOCKPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued. The current stock price of ₹1,886.30 is trading 28.8% above its estimated GF Value™ of ₹1,464.07. GuruFocus considers Wockhardt to be Modestly Overvalued.

Key valuation signals for NSE:WOCKPHARMA:

  • Other Stockholders Equity: ₹0 Mil
  • GF Value™: ₹1,464.07 vs. price of ₹1,886.30 (28.8% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the NSE:WOCKPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Wockhardt Business Description

Other Exchanges 532300:India
Address Bandra-Kurla Complex, Wockhardt Towers, Bandra East, Mumbai, MH, IND, 400051
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
60GF Score

Get the complete analysis for NSE:WOCKPHARMA

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,886.30
Price
₹1,464.07
GF Value